A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

Summary

The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.

Timeline

Start

2024-05-30

Primary completion

2027-02-22

Completion

2027-08-13

Drugs

Indications